SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Status:
Not yet recruiting
Trial end date:
2026-02-28
Target enrollment:
Participant gender:
Summary
This study is a single arm, multi-center, open label phase Ib/II study of SC0245 and
Irinotecan combination therapy in subjects with extensive-stage small cell lung cancer
(ES-SCLC) as a second therapy. This study will have three parts, phase 1 dose escalation
(Part 1), phase 1 dose expansion (Part 2), and phase 2 combination therapy (Part 3).